Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

By J. Markert, Medlock, S. Rabkin, G. Gillespie, T. Todo, William D. Hunter, C. Palmer, F. Feigenbaum, C. Tornatore, F. Tufaro and 1 more. Gene Therapy, 2000

990 citations recorded by the source corpus.

Subfields: Epidemiology, Genetics, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/7a5032056c6f1560c1420be59c2a9bc8da4b78c1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. María García
2. M. Esteban
3. Susana Guerra
4. I. Ventoso
5. J. Gil
6. E. Domingo
7. C. Rivas

Citations in the corpus

• A Phase III Clinical Evaluation of Herpes Simplex Virus Type 1 Thymidine Kinase and Ganciclovir Gene Therapy as an Adjuvant to Surgical Resection and Radiation in Adults with Previously Untreated Glioblastoma Multiforme (2000, neutral): “Replicating virus vectors (oncolytic viruses), e.g., HSV or adenovirus (Heise et al., 1999; Markert et al., 2000), could expand the intra-and peritumoral range of action of local gene therapy.”
• Impact of Protein Kinase PKR in Cell Biology: from Antiviral to Antiproliferative Action (2006, background): “protein, for specific regression of malignant glioma (241, 291).”
• Herpes simplex viruses: is a vaccine tenable? (2002, background): “G207, a conditionally replicating HSV mutant, has been evaluated in a phase I safety trial for a subset of patients with unresponsive recurrent malignant gliomas (52).”